Study S001931

A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus.

ClinicalTrials.gov record

Registration

Registration: NCT07599410
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 240
Start: 2026-07-14
Primary completion: 2027-05
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: T2DM
Interventions: DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in glycated hemoglobin (HbA1c) relative to baseline [Week 20.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.